Introduction {#Sec1}
============

Vestibular schwannomas (VS) are benign neoplastic proliferations recapitulating the differentiation repertoire of the myelin-forming Schwann cells of the vestibular branch of the vestibulocochlear nerve in the internal auditory canal or the cerebellopontine angle. These tumors often display a slow and self-limiting growth pattern but there are also variants that progress more rapidly and persistently. In these patients, ongoing tumor progression can eventually cause brainstem compression or paralysis of adjacent cranial nerves. In most cases (\> 90%), VS occur as unilateral sporadic tumors \[[@CR1]\], whereas bilateral tumors are pathognomonic for the hereditary disorder neurofibromatosis type 2 (NF2) \[[@CR2]\]. Loss of function of the tumor suppressor protein merlin, encoded by the *NF2* gene, is an essential step in schwannoma pathogenesis \[[@CR3], [@CR4]\]. Heterozygous germline inactivating mutations affecting the *NF2* gene cause neurofibromatosis type 2 while biallelic somatic mutations of *NF2* are found in sporadic VS \[[@CR4]\]. Recent years showed an increase in the number of newly diagnosed VS to approximately 20 per million people per year \[[@CR5]--[@CR7]\]. This phenomenon most probably is the result of more frequent use of magnetic resonance imaging scanning (MRI), which in turn leads to the identification of more subclinical cases of VS.

Management of these VS comprises several options. The initial policy for smaller tumors is to wait and see by performing sequential MRI scans. In case of large tumors or when tumors rapidly progress active treatment is needed. Current therapeutic management of VS consists of microsurgery or radiotherapy. In selected cases of NF2-related tumors, pharmacotherapeutic options are also applied \[[@CR8]--[@CR10]\]. This kind of therapy is not used for sporadic VS. One of the clinical dilemmas in selecting the most suitable treatment policy for VS is the unpredictable behavior these tumors can display. Some tumors remain stable for decades while others double in size within less than a year. So far, cystic degeneration is the only known prognostic marker for progressive tumor volume growth \[[@CR11]\]. Better prediction of tumor volume progression will improve the accuracy of determining the correct moment and modality of therapeutic intervention. More understanding of tumor behavior requires more insight into tumor biological factors influencing tumor development. Investigating VS biology not only benefits the understanding of its growth pattern but it will also contribute to the identification of potential therapeutic targets.

In two earlier papers on the inflammatory microenvironment in VS, we demonstrated a relationship between tumor-associated macrophages (TAM), angiogenesis, and tumor growth \[[@CR12], [@CR13]\]. These results were in line with the emerging notion that intratumoral inflammation is a major driving force behind the volumetric progression of tumors \[[@CR14]--[@CR16]\]. The fact that TAM may form a target for therapy emphasizes their potential clinical importance \[[@CR17]\]. TAM consist of a heterogeneous population of, mainly alternatively activated, M2-type macrophages that seem to have tumor promoting characteristics \[[@CR16], [@CR18]\]. Inhibiting the formation of M2 macrophages may therefore have a negative effect on tumor progression. An important regulator within the inflammatory microenvironment capable of polarizing macrophages towards an M2-like phenotype is a cytokine known as the macrophage colony stimulating factor, or M-CSF \[[@CR19]\]. The exact role of M-CSF in macrophage associated tumor development remains to be elucidated but its function as a promoter of tumor progression has been indicated in several tumor models \[[@CR20]--[@CR22]\]. Another regulating protein that seems to be capable of skewing the microenvironment into a tumor promoting direction is interleukin-34 (IL-34). This cytokine was first described in 2008 by Lin et al. \[[@CR23]\] and displays common features with M-CSF in such a way that they appear to have synergistic functions \[[@CR24], [@CR25]\]. Consistent with these findings, relatively recent studies have indicated that IL-34 seems to be associated with tumor progression in osteosarcoma and lung cancer \[[@CR26], [@CR27]\].

The aim of this study was to analyze the expression of M-CSF and IL-34 in our earlier described cohort of 20 sporadic vestibular schwannoma patients and to determine whether their expression can be related to clinicopathologic characteristics and tumor growth.

Materials and methods {#Sec2}
=====================

We performed immunohistochemical stains against M-CSF and IL-34 on formalin-fixed paraffin-embedded vestibular schwannoma tissue. To investigate whether there is a relationship between the presence of these proteins and VS progression, we analyzed their expression pattern in the same selection of tumors that we previously analyzed and described for the expression of tumor-associated macrophages \[[@CR12]\]. This selection of tumor samples consisted of ten radiologically observed fast-growing tumors and ten radiologically observed slower growing tumors. The expression patterns of M-CSF and IL-34 within these groups were compared with each other. The already published data on angiogenesis and macrophage expression was also included into this analysis, as well as radiological data regarding cystic degeneration.

Patient selection {#Sec3}
-----------------

A retrospective selection was made from vestibular schwannoma database of the Leiden University Medical Center. This group of patients had been consecutively treated for a proven sporadic vestibular schwannoma from January 2006 to December 2011. Two different cohorts were compiled out of a total of 46 consecutively treated patients. All patients had at least two preoperative MRI scans on the basis of which volumetric tumor growth was measured. The first cohort included the ten patients with the slowest growing tumors, while the second cohort included the ten fastest growing tumors. The decision for surgical treatment had been based upon symptoms (e.g., vertigo, hearing loss, and tinnitus), tumor size, tumor growth, and patients' personal preference. No NF2-related tumors were included in the analysis.

To ensure patients' privacy, all samples were managed in a coded fashion and all procedures were conducted according to the Code for Proper Secondary Use of Human Tissue in the Netherlands (Dutch Federation of Medical Scientific Societies).

Tumor measurement {#Sec4}
-----------------

The measurement of all tumors was performed on T1-weighted gadolinium-enhanced MRI scans and conducted by one and the same author. Tumor volume was determined with a contour measurement method using Vitrea View software (Vital Imaging, Minnetonka, MN, USA). To increase the accuracy of the measurements, each volume was determined two times per MRI scan. The mean of these two measurements was used for further evaluation of tumor growth. By calculating the difference in tumor volume on sequential MRI investigations, tumor growth rate could be determined. Volumetric growth was expressed as the increase in milliliters per year. Next to measuring tumor growth rate, the presence of cystic degeneration was evaluated. Figure [1](#Fig1){ref-type="fig"} shows volume measurements of a fast-growing and a slow-growing tumor.Fig. 1**a** and **b** A fast-growing tumor with an average growth of 9 ml per year. **c** and **d** A slower growing tumor with an average growth of 0.2 ml per year

Immunohistochemistry {#Sec5}
--------------------

Immunohistochemistry was performed on 4-μm thick slides acquired form formalin-fixed paraffin-embedded vestibular schwannoma tissue samples. All staining procedures were conducted on one and the same tumor block per tumor sample. The exact materials and methods that were applied for the CD31 and CD163 stains are described in the earlier mentioned paper on tumor-associated macrophages \[[@CR12]\]. Immunohistochemical stains for M-CSF (pre-incubation and incubation in 5% non-fat milk in PBS/1%BSA, 1:100 diluted, anti-M-CSF antibody, ab52864, Abcam, Cambridge, MA, USA) and IL-34 (pre-incubation and incubation in 5% non-fat milk in PBS/1%BSA, 1:3000, anti-interleukin-34 antibody, ab224734, Abcam, Cambridge, MA, USA) were performed according to standard laboratory methods \[[@CR28]\]. Tonsil served as positive control for M-CSF and hepatocellular carcinoma and prostate carcinoma were used as positive control tissues for IL-34.

Microscopic analysis {#Sec6}
--------------------

Immunostainings were evaluated by two separate observers (W. de Vries and P. Hogendoorn) without knowledge of clinical patient data. M-CSF as well as IL-34 showed a varying staining pattern with areas of strong expression and areas of weak expression within the same tumor. Additionally, several tumor specimens showed hemosiderin deposition mimicking positive staining. This made computerized quantification less reliable. For this reason, a semiquantitative immunohistochemistry score of the overall staining intensity was made for each tumor sample. Staining intensity was initially categorized as no staining, weak staining, moderate staining, and strong staining. Exact details regarding M2 macrophage (CD163) and angiogenesis (CD31) staining and scoring techniques are described in our earlier report \[[@CR12]\].

Statistical analysis {#Sec7}
--------------------

The difference in M-CSF and IL-34 expression in fast- versus slow-growing tumors and cystic versus non-cystic tumors was determined with the Fisher's exact test. The Mann-Whitney *U* test was used to determine the relation between the expression of M-CSF and IL-34 and the degree of microvessel density and CD163 expression. This test was also used to see if there was a relation between cystic degeneration and CD-163 expression. For all statistical tests a level of significance of *p* \< 0.05 was taken into account. Calculations were made using SPSS version 16.0, IBM, Inc.

Results {#Sec8}
=======

Details regarding patient characteristics are listed in Table [1](#Tab1){ref-type="table"}. There were no significant differences in distribution of age, sex, and duration of preoperative follow-up between the two patient groups. As expected, the distribution of tumor growth rate and tumor volume as well as cystic degeneration was significantly different in the two groups. Analysis of the immunohistochemical stainings showed the following results. All samples were M-CSF positive, demonstrating mainly cytoplasmic expression in an irregular staining pattern (Fig. [2](#Fig2){ref-type="fig"}). Nine samples showed weak staining, four samples showed moderate staining, and seven samples showed strong staining. Based on these results, we simplified the categories of staining to weak and strong staining, the latter being the combination of moderate and strong staining. M-CSF staining was significantly higher in the group of fast-growing tumors (*p* = 0.003). M-CSF expression is also significantly higher (*p* = 0.035) in cystic tumors (Table [2](#Tab2){ref-type="table"}). CD163 expression was significantly higher in tumors with strong M-CSF expression (*p* = 0.003). There was no significant relation between microvessel density and M-CSF expression.Table 1Patient characteristicsCaseSexAge (years)Tumor volume (ml)Growth rate (ml/year)Preoperative MRI follow-up (months)CysticSlow-growing group L3721M600.350.0613No L3742F540.270.217Yes L3773F520.220.076No L3774F500.880.1927No L3775M530.690.1710No L3779F511.460.1832Yes L3780F560.740.2511No L3781F440.530.1912No L3787M580.520.1812No L3797F602.130.2312No Mean (±SD)53.8 (± 4.96)0.77 (± 0.59)0.17 (± 0.06)14.2 (± 8.46)Fast-growing group L3725F623.261.3311No L3731F8114.414.4119Yes L3733F7611.668.8410No L3740F522.272.507No L3741F717.251.8321Yes L3745F565.622.186Yes L3746M4630.7343.984Yes L3792F756.923.4321Yes L3793F397.325.5210Yes L3805F3923.052.909Yes Mean (±SD)59.7 (± 15.65)11.24 (± 9.16)7.69 (± 12.94)11.8 (± 6.26) Difference fast versus slow (*p*)0.26a0.41b*\< 0.0001b\< 0.0001b*0.31b*0.007a*a, chi-square test; b, Mann-Whitney *U* test; results at *p* ≤ 0.05 are shown in italicsFig. 2**a** Weak expression of M-CSF. **b** Strong expression of M-CSF. **c** A tissue area with weak IL-34 expression. **d** A tissue area with strong IL-34 expressionTable 2Fisher's exact test for M-CSF and IL-34 expressionM-CSF stainingIL-34 stainingWeakStrongModerateStrongGrowth rate Slow8246 Fast1946Total911812*p* value*0.003*0.675Cystic degeneration No7355 Yes2837Total911812*p* value*0.035*0.325Results at *p* ≤ 0.05 are shown in italics

Analysis of IL-34 showed that all tumors displayed mostly cytoplasmic immunopositivity for this protein (Fig. [1](#Fig1){ref-type="fig"}). Similar to M-CSF, the intratumoral staining pattern of IL-34 was irregular. Eight tumors showed moderate staining and the remaining 12 tumors showed strong staining. Statistical analysis of our scoring results showed no significant differences in IL-34 expression when it comes to tumor growth, cystic degeneration, CD-163 expression, or microvessel density.

Finally, cystic tumors showed a significantly higher degree of CD-163 expression compared to non-cystic tumors (*p* = 0.005).

Discussion {#Sec9}
==========

Inflammation is an important feature of almost every type of neoplasm. The inflammatory process that takes places within tumors is often characterized by the abundance of tumor-associated macrophages \[[@CR16]\]. The influx of these cells and their immunomodulating capacities allow the progression of tumor cells by stimulating processes such as of angiogenesis and cell survival \[[@CR15]\]. M-CSF and IL-34 are cytokines that regulate macrophage recruitment, proliferation, and differentiation \[[@CR24]\]. More specifically, M-CSF and recently also IL-34 are identified as important factors that polarize macrophages towards a protumoral M2 phenotype \[[@CR22], [@CR27]\]. High M-CSF expression and subsequent increased macrophage levels have been associated with disease progression and unfavorable outcome in several types of tumors \[[@CR20], [@CR21], [@CR29]\] and similar findings are reported for IL-34 \[[@CR26], [@CR27]\].

Our earlier studies showed that VS can contain large quantities of TAM, and their presence seems to be related to tumor expansion. In this study, we attempted to find out if M-CSF and IL-34 are part of this process as well by comparing their expression pattern in progressive versus more indolent VS. A necessary condition to examine tumor tissue is that patients are surgically treated. One of the main indications for surgery is tumor growth. Even the group of slow-growing tumors showed a certain form of volumetric growth and therefore did not fully represent the truly indolent tumors. This unavoidable selection bias makes the identification of biological differences between indolent versus progressive variants of VS more challenging.

In this report, we demonstrate the presence of M-CSF and IL-34 in VS. The expression of M-CSF is higher in fast-growing VS compared to slower growing VS and, in accordance with its supposed function, the presence of M-CSF seems to be related to the expression of TAM within VS. Furthermore, the expression of M-CSF as well as the number of CD-163 positive macrophages appears to be higher in cystic tumors. We therefore postulate that intratumoral inflammation might also contribute to the pathogenesis of cystic degeneration. We could not demonstrate a relation between IL-34 expression and clinicopathologic characteristics of VS in our study group. Nevertheless, it should be noted that this protein was at least moderately expressed by all tumors, more than half of which even showed high immunopositivity. These relatively small intertumoral differences in expression of IL-34 together with the above mentioned selection bias may be a reason why we were unable to find a significant difference in the expression pattern of this protein.

It is important to note that the results of our comparisons are observations of association. There is always the possibility that these findings are epiphenomena of a larger biological growth process and therefore not directly related to each other. The fact remains that the results of this study seem to be in line with our earlier presented data on macrophage expression in VS. These current observations provide additional support for our hypothesis that the inflammatory microenvironment plays an essential role in the progression of these tumors. By modulating the characteristics of this microenvironment through the inhibition of M-CSF, and maybe IL-34, the progression of VS may in turn be decreased. For M-CSF, several clinical trials with inhibitors such as PLX3397 (pexidartinib) and RG7155 (emactuzumab) showed promising results in a variety of neoplasms \[[@CR30], [@CR31]\]. IL-34 might be a potential target as well but clinical evidence remains to be provided \[[@CR32]\]. Before applying anti-*M-CSF* or anti-*IL-34* therapy in VS patients, in vivo schwannoma models would be very helpful to further elucidate the biological mechanisms that are involved in the associations observed in this study. Unfortunately, the current lack of sporadic vestibular schwannoma cell lines hampers such functional studies.
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